Document Detail

Immune responses and safety after dart or booster vaccination of bison with Brucella abortus strain RB51.
MedLine Citation:
PMID:  22461528     Owner:  NLM     Status:  MEDLINE    
One alternative for management of brucellosis in Yellowstone National Park bison (Bison bison) is vaccination of calves and yearlings. Although Brucella abortus strain RB51 vaccination protects bison against experimental challenge, the effect of booster vaccinations was unknown. This study characterized immunologic responses after dart or booster vaccination of bison with Brucella abortus strain RB51. In two studies, 8- to 10-month-old female bison were inoculated with saline (n = 14), hand vaccinated with 1.1 × 10(10) to 2.0 × 10(10) CFU of RB51 (n = 21), or dart vaccinated with 1.8 × 10(10) CFU of RB51 (n = 7). A subgroup of hand vaccinates in study 1 was randomly selected for booster vaccination 15 months later with 2.2 × 10(10) CFU of RB51. Compared to single vaccinates, booster-vaccinated bison had greater serologic responses to RB51. However, there was a trend for antigen-specific proliferative responses of peripheral blood mononuclear cells (PBMC) from booster vaccinates to be reduced compared to responses of PBMC from single vaccinates. PBMC from booster vaccinates tended to have greater gamma interferon (IFN-γ) production than those from single vaccinates. In general, dart vaccination with RB51 induced immunologic responses similar to those of hand vaccination. All vaccinates (single hand, dart, or booster) demonstrated greater (P < 0.05) immunologic responses at various times after vaccination than nonvaccinated bison. Booster vaccination with RB51 in early gestation did not induce abortion or fetal infection. Our data suggest that booster vaccination does not induce strong anamnestic responses. However, phenotypic data on resistance to experimental challenge are required to fully assess the effect of booster vaccination on protective immunity.
S C Olsen; C Johnson
Related Documents :
22711628 - Components of protective immunity.
22854668 - Size of clinical trials and introductory prices of prophylactic vaccine series.
22371638 - Vaccination with dendritic cells pulsed with hepatitis c pseudo particles induces speci...
22686468 - Saccharomyces as a vaccine against systemic candidiasis.
24968078 - Immune parameters in the intestine of wild and reared unvaccinated and vaccinated atlan...
15745228 - Hyaluronic acid and its use as a "rejuvenation" agent in cosmetic dermatology.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2012-03-29
Journal Detail:
Title:  Clinical and vaccine immunology : CVI     Volume:  19     ISSN:  1556-679X     ISO Abbreviation:  Clin. Vaccine Immunol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-27     Completed Date:  2012-08-15     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101252125     Medline TA:  Clin Vaccine Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  642-8     Citation Subset:  IM    
Bacterial Diseases of Livestock Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, Iowa, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Bacterial / blood
Brucella Vaccine / administration & dosage,  adverse effects*,  immunology*
Brucella abortus / immunology*
Brucellosis / immunology,  veterinary*
Cell Proliferation
Interferon-gamma / secretion
Leukocytes, Mononuclear / immunology
Vaccination / adverse effects*,  methods*
Reg. No./Substance:
0/Antibodies, Bacterial; 0/Brucella Vaccine; 82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.
Next Document:  Added value of use of a purified protein derivative-based enzyme-linked immunosorbent spot assay for...